Mandate

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").

The facility is located in Strängnäs and provides specialised expertise and comprehensive services, supporting the development and manufacturing of oral solids and with specialist infrastructure for beta-lactam production. APL, which is now acquiring the facility, is a wholly state-owned company with a social mission to develop and provide a medically appropriate and quality-assured range of extemporaneous medicines and stock preparations. The acquisition is an important step for the Swedish government in strengthening Sweden's preparedness and ensuring access to essential medicines in Sweden, particularly in crisis situations.

Read more on the Government's website here.

Vinge's team consisted of among others Jonas Bergström, Per Kling and Ellenor Eckerborn (M&A), Mathilda Persson and Siri Blomberg (Corporate Commercial), Åsa Hellstadius and Ian Jonson (Life Science).

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025